Reviews
Average rating: 3/5
Physician ( 1 )
-
5
-
4
-
3
-
2
-
1
Average rating: 3.00/5
Total Reviews: 1
-
5
-
4
-
3
-
2
-
1
Alirocumab (Praluent) is a PCSK9 inhibitor that can lower LDL cholesterol by 50–60% and has proven benefit in reducing cardiovascular events. I consider it for patients with familial hypercholesterolemia or established ASCVD whose LDL remains above goal despite maximally tolerated statins and ezetimibe. Because it is costly and requires injections, I reserve it as a third-line option when aggressive cholesterol lowering is still needed.
0